Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 440

1.

Assessing the validity, responsiveness and meaningfulness of the Hidradenitis Suppurativa Clinical Response (HiSCR) as the clinical endpoint for hidradenitis suppurativa treatment.

Kimball AB, Jemec GB, Yang M, Kageleiry A, Signorovitch JE, Okun MM, Gu Y, Wang K, Mulani P, Sundaram M.

Br J Dermatol. 2014 Dec;171(6):1434-42. doi: 10.1111/bjd.13270. Epub 2014 Nov 11.

PMID:
25040429
2.

HiSCR (Hidradenitis Suppurativa Clinical Response): a novel clinical endpoint to evaluate therapeutic outcomes in patients with hidradenitis suppurativa from the placebo-controlled portion of a phase 2 adalimumab study.

Kimball AB, Sobell JM, Zouboulis CC, Gu Y, Williams DA, Sundaram M, Teixeira HD, Jemec GB.

J Eur Acad Dermatol Venereol. 2016 Jun;30(6):989-94. doi: 10.1111/jdv.13216. Epub 2015 Jul 22.

3.

A double-blind placebo-controlled randomized trial of adalimumab in the treatment of hidradenitis suppurativa.

Miller I, Lynggaard CD, Lophaven S, Zachariae C, Dufour DN, Jemec GB.

Br J Dermatol. 2011 Aug;165(2):391-8. doi: 10.1111/j.1365-2133.2011.10339.x. Epub 2011 Jun 30.

PMID:
21457202
4.

Adalimumab Treatment in Women With Moderate-to-Severe Hidradenitis Suppurativa from the Placebo-Controlled Portion of a Phase 2, Randomized, Double-Blind Study.

Gottlieb A, Menter A, Armstrong A, Ocampo C, Gu Y, Teixeira HD.

J Drugs Dermatol. 2016 Oct 1;15(10):1192-1196.

PMID:
27741335
5.

Adalimumab for the treatment of moderate to severe Hidradenitis suppurativa: a parallel randomized trial.

Kimball AB, Kerdel F, Adams D, Mrowietz U, Gelfand JM, Gniadecki R, Prens EP, Schlessinger J, Zouboulis CC, van der Zee HH, Rosenfeld M, Mulani P, Gu Y, Paulson S, Okun M, Jemec GB.

Ann Intern Med. 2012 Dec 18;157(12):846-55. doi: 10.7326/0003-4819-157-12-201212180-00004.

PMID:
23247938
6.

Long-term successful adalimumab therapy in severe hidradenitis suppurativa.

Blanco R, Martínez-Taboada VM, Villa I, González-Vela MC, Fernández-Llaca H, Agudo M, González-López MA.

Arch Dermatol. 2009 May;145(5):580-4. doi: 10.1001/archdermatol.2009.49.

PMID:
19451504
7.

A prospective open-label clinical trial of adalimumab for the treatment of hidradenitis suppurativa.

Amano M, Grant A, Kerdel FA.

Int J Dermatol. 2010 Aug;49(8):950-5. doi: 10.1111/j.1365-4632.2010.04545.x.

PMID:
21128923
8.

Adalimumab: A Review in Hidradenitis Suppurativa.

Kim ES, Garnock-Jones KP, Keam SJ.

Am J Clin Dermatol. 2016 Oct;17(5):545-552. Review.

PMID:
27665300
9.

An open-label study of anakinra for the treatment of moderate to severe hidradenitis suppurativa.

Leslie KS, Tripathi SV, Nguyen TV, Pauli M, Rosenblum MD.

J Am Acad Dermatol. 2014 Feb;70(2):243-51. doi: 10.1016/j.jaad.2013.09.044. Epub 2013 Dec 4.

PMID:
24314876
10.

Combination of oral zinc gluconate and topical triclosan: An anti-inflammatory treatment modality for initial hidradenitis suppurativa.

Hessam S, Sand M, Meier NM, Gambichler T, Scholl L, Bechara FG.

J Dermatol Sci. 2016 Nov;84(2):197-202. doi: 10.1016/j.jdermsci.2016.08.010. Epub 2016 Aug 10.

PMID:
27554338
11.

A prospective open-label clinical trial of efficacy of the every week administration of adalimumab in the treatment of hidradenitis suppurativa.

Sotiriou E, Goussi C, Lallas A, Chovarda E, Apalla Z, Lazaridou E, Ioannides D.

J Drugs Dermatol. 2012 May;11(5 Suppl):s15-20.

PMID:
22644772
12.

Resorcinol peels as a possible self-treatment of painful nodules in hidradenitis suppurativa.

Boer J, Jemec GB.

Clin Exp Dermatol. 2010 Jan;35(1):36-40. doi: 10.1111/j.1365-2230.2009.03377.x. Epub 2009 Jun 22.

PMID:
19549239
13.

Experience with ustekinumab for the treatment of moderate to severe hidradenitis suppurativa.

Gulliver WP, Jemec GB, Baker KA.

J Eur Acad Dermatol Venereol. 2012 Jul;26(7):911-4. doi: 10.1111/j.1468-3083.2011.04123.x. Epub 2011 May 24.

PMID:
21605174
14.

Use of biological treatments in patients with hidradenitis suppurativa.

Martin-Ezquerra G, Masferrer E, Masferrer-Niubò M, Ferran M, Sánchez-Regaña M, Collgros H, Bordas X, Notario J, Alsina M, Gil I, Izquierdo N, Aparicio G, Mollet J, Garcia-Patos V, Pujol RM.

J Eur Acad Dermatol Venereol. 2015 Jan;29(1):56-60. doi: 10.1111/jdv.12438. Epub 2014 Mar 13.

PMID:
24629001
15.

Comparing treatment outcome of infliximab and adalimumab in patients with severe hidradenitis suppurativa.

van Rappard DC, Leenarts MF, Meijerink-van 't Oost L, Mekkes JR.

J Dermatolog Treat. 2012 Aug;23(4):284-9. doi: 10.3109/09546634.2011.571657. Epub 2011 Jul 14.

PMID:
21756155
16.

Hidradenitis suppurativa in the pediatric population.

Liy-Wong C, Pope E, Lara-Corrales I.

J Am Acad Dermatol. 2015 Nov;73(5 Suppl 1):S36-41. doi: 10.1016/j.jaad.2015.07.051. Review.

PMID:
26470613
17.

Evidence-based approach to the treatment of hidradenitis suppurativa/acne inversa, based on the European guidelines for hidradenitis suppurativa.

Gulliver W, Zouboulis CC, Prens E, Jemec GB, Tzellos T.

Rev Endocr Metab Disord. 2016 Sep;17(3):343-351. Review.

18.

AISI: A New Disease Severity Assessment Tool for Hidradenitis Suppurativa.

Chiricozzi A, Faleri S, Franceschini C, Caro RD, Chimenti S, Bianchi L.

Wounds. 2015 Oct;27(10):258-64.

PMID:
26479209
19.

Adalimumab (antitumour necrosis factor-α) treatment of hidradenitis suppurativa ameliorates skin inflammation: an in situ and ex vivo study.

van der Zee HH, Laman JD, de Ruiter L, Dik WA, Prens EP.

Br J Dermatol. 2012 Feb;166(2):298-305. doi: 10.1111/j.1365-2133.2011.10698.x.

PMID:
22013960
20.

New insights into the diagnosis of hidradenitis suppurativa: Clinical presentations and phenotypes.

van der Zee HH, Jemec GB.

J Am Acad Dermatol. 2015 Nov;73(5 Suppl 1):S23-6. doi: 10.1016/j.jaad.2015.07.047. Review.

PMID:
26470610

Supplemental Content

Support Center